Drug Sponsors

Foundry Medical Innovations to re-tool with merger and name change

Wednesday, May 20, 2015 03:19 PM

Foundry Medical Innovations, a Carslbad, Calif.-based comprehensive medical and diagnostic device development company, has merged with Zeis Consulting Group, a provider of IVD clinical research, and changed its name to Toolbox Medical Innovations to better leverage its strengths and serve its growing list of clients.

More... »


AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden

Wednesday, May 20, 2015 03:18 PM

AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company's global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

More... »


Lannett to acquire Silarx Pharmaceuticals

Wednesday, May 20, 2015 03:17 PM

Lannett, a Philadelphia, Pa.-based developer and marketer of generic pharmaceutical products, has signed a definitive agreement to acquire privately held, New York-based Silarx Pharmaceuticals and a related real estate entity, a manufacturer and marketer of liquid generic pharmaceutical products. The transaction is expected to close in early June, subject to customary closing conditions. Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research R&D experience and added diversity to Lannett’s portfolio of existing and pipeline products.  

More... »

Forum Pharmaceuticals relocates headquarters to Waltham, Massachusetts

Wednesday, May 20, 2015 03:15 PM

Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.

More... »

Endo to acquire Par Pharmaceutical for $8 billion

Monday, May 18, 2015 01:06 PM

Ireland-based Endo International has agreed to acquire privately held, Woodcliff Lake, N.J.-based Par Pharmaceutical from TPG for $8.05 billion, including assumption of Par debt. The transaction has been unanimously approved by the boards of directors of both Endo and Par and is supported by the management teams of both companies. There are no further shareholder approvals required.

More... »

Redx Pharma launches third subsidiary, Redx Immunology

Monday, May 18, 2015 01:05 PM

Redx Pharma has launched its third subsidiary, Redx Immunology, which will focus on developing new therapies for disorders of the immune system.

More... »

Circassia to acquire Aerocrine and Prosonix

Monday, May 18, 2015 01:03 PM

Circassia Pharmaceuticals has made an all cash offer to acquire Aerocrine, a Swedish company focused on the development and commercialization of medical diagnostic products for use in the diagnosis and management of patients with asthma, for up to $216.4 million.

More... »

Denali Therapeutics launches to study neurodegenerative disease treatments

Friday, May 15, 2015 02:23 PM

Denali Therapeutics, a new California-based biotechnology company focused on developing effective therapies for neurodegenerative diseases, has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer's disease, Parkinson's disease, ALS and other neurodegenerative diseases.

More... »

California Life Sciences Association launches, following BayBio, California Healthcare Institute merger

Friday, May 15, 2015 02:18 PM

The California Life Sciences Association (CLSA) has officially launched as a representation for California’s life sciences sector. CLSA now is the largest state and regional life sciences advocacy group in the country, with more than 750 members. The organization advances California’s life sciences innovation ecosystem by advocating for effective national, state and local public policies and supporting entrepreneurs and life sciences businesses. CLSA is the result of a completed merger between BayBio and California Healthcare Institute.

More... »

Pfizer acquires minority interest in AM-Pharma; secures option to acquire company

Wednesday, May 13, 2015 12:15 PM

Pfizer has acquired a minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company.

More... »

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs